<DOC>
	<DOC>NCT02320214</DOC>
	<brief_summary>To evaluate the safety of Miami w/ frag Personal lubricant when used as indicated as a personal lubricant in the vagina and vulvar/perineal areas at least four times weekly for two weeks in a population of healthy females.</brief_summary>
	<brief_title>A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Erythema</mesh_term>
	<criteria>Subject is female between the ages of 18 and 49 years (at lease 21 subjects) or 5060 years (no more than 9 subjects); Subject is using adequate nonbarrier method of birth control [established us of hormonal methods of contraception (oral, injected, implanted, or patch), intrauterine device (IUD) or intrauterine system (IUS), surgical sterilization (e.g. in a monogamous relationship with male partner with vasectomy]; Subject is free of any vaginal disorders; Subject is sexually active and in a monogamous, heterosexual relationship, and whose male partner is willing and able to give informed consent and agrees to engage in sexual intercourse at least twice each week during the twoweek study (at least 50% and up to 100% of the study population) or is not sexually active (no more than 50% of the population); Subject is a personal lubricant user and agrees to replace her usual personal lubricant with the investigational product; Subject has normal menstrual cycle and is not expected to menstruate 24 days before or after the examination days; Subject agrees to use the provided investigational product at least four times weekly (including at least twice weekly during sexual intercourse for subjects with monogamous, male partners) over the twoweek study period; Subject exhibits no clinically significant evidence of vulvar or vaginal irritation, as determined by a study doctor, and no reports of sensory irritation at the baseline examination; Subject is willing to refrain from introducing any new vaginal products, or using vaginal medication or local contraceptives (including condoms and hormonal rings), during the course of this study; Subject agrees to refrain from douching or using any medications, powder, lotions or personal care products in the vulvar or perianal area for the duration of the study (Note: subjects may continue to use their usual pantyliner, if any); Subject is willing to use a urine pregnancy test provided to them at baseline and on the third visit (Week 2, day 14); Subject has a standard Clinical Research Laboratories, Inc. (CRL) Medical History form on file at CRL and has completed study specific Medical History and Screener/Inclusion forms; Subject has signed and, if sexually active and in a monogamous relationship, whose partner has signed, an Informed Consent Form (ICF) in compliance with 21 CFR Part 50: "Protection of Human Subjects"; Subject (and male partner, if applicable) has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164; Subject is dependable and able to follow directions as outlined in the protocol; Subject receives a score of 0 or 0.5 for erythema and edema, and 0 for sensorial irritation (burning, stinging, itching, and dryness) during the first examination. Subject is pregnant, nursing, or planning a pregnancy; Subject is postmenopausal or has had a hysterectomy; Subject is currently using, or has used within two weeks prior to study initiation, any systemic or topical corticosteroids, vasoconstrictors, antibiotics, antiinflammatories, or antihistamines; Subject has known allergies to vaginal or any cosmetic products (including lotions, moisturizer, powder, sprays, etc.); Subject reports a history of recurrent bladder, vaginal infection, or incontinence; Subject exhibits or reports gynecological abnormalities or has had vaginitis within 60 days prior to study initiation. Subject is expected to menstruate 24 days before or after the time of the first, second, and third examination; Subject uses a vaginal ring, diaphragm or cervical/vault caps, condoms, or condoms with spermicide as a means of contraception; Subject has participated in a study involving the vaginal area or in an investigational systemic drug study within two weeks of study initiation; Subject receives a score higher than 0.5 for erythema, edema, or &gt;0 for burning, stinging, or itching, during the first examination or shows any other sign of mucosal irregularities (dryness, papules, vesticulation, fissure).</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>